Alkylating agent linked to therapy-related leukemia

Alkylating agent linked to therapy-related leukemia
For patients treated for Hodgkin's lymphoma, cumulative doses of alkylating agent is associated with the risk of therapy-related acute myeloid leukemia/myelodysplastic syndrome, according to a study published online Jan. 7 in the Journal of Clinical Oncology.

(HealthDay)—For patients treated for Hodgkin's lymphoma (HL), cumulative doses of alkylating agent (AA) is associated with the risk of therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS), according to a study published online Jan. 7 in the Journal of Clinical Oncology.

Michael Zach Koontz, M.D., from the Stanford University Medical Center in California, and colleagues reviewed the records of 754 patients with HL (treated from 1974 to 2003) with at least five years of follow-up after completing therapy in successive generations of Stanford clinical trials. S studies (1974 to 1980) and C studies (1981 to 1989) utilized extended-field , while G studies (1989 to 2003) utilized involved-field radiotherapy. Primary chemotherapies varied by study.

The researchers found that, in the G studies, the cumulative exposure to AA was substantially lower than in the S and C studies, with a 75 to 83 percent lower dose of nitrogen mustard and omission of procarbazine and . t-AML/MDS developed in 24 patients, 15 following primary chemotherapy and nine after salvage for relapsed HL. G studies had a significantly lower incidence of t-AML/MDS (0.3 percent) compared with the S (5.7 percent) or C (5.2 percent) studies. No t-AML/MDS was seen in G studies after primary therapy. No patient from the G studies developed t-AML-MDS after primary therapy; t-AML/MDA developed in one patient from the G studies following second-line therapy.

"Our data demonstrate the relationship between the cumulative AA dose and t-AML/MDS," the authors write. "The prognosis for t-AML/MDS is dismal, and it is imperative that therapies minimize these risks."

One author disclosed financial ties to the pharmaceutical industry.


Explore further

Data presented demonstrate prolonged overall survival for patients with acute myeloid leukemia

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Journal of Clinical Oncology

Copyright © 2013 HealthDay. All rights reserved.

Citation: Alkylating agent linked to therapy-related leukemia (2013, January 15) retrieved 12 April 2021 from https://medicalxpress.com/news/2013-01-alkylating-agent-linked-therapy-related-leukemia.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments